论文部分内容阅读
目的观察贝那普利联合厄贝沙坦治疗慢性心衰伴蛋白尿的疗效。方法 116例慢性心衰伴蛋白尿患者随机分为贝那普利组38例、厄贝沙坦组38例及联合治疗组40例,在心衰综合治疗基础上分别予以贝那普利、厄贝沙坦及两者联合治疗,10～12周后观察临床疗效及临床指标变化。结果联合治疗组临床治疗总有效率明显优于贝那普利及厄贝沙坦组(P<0.05);各组治疗后UP,BUN,Cr,NT-proBNP,LVDd,收缩压和舒张压均较治疗前显著下降(P<0.05或P<0.01),LVEF升高(P<0.01);治疗后联合治疗组与其他2组相比,UP,BUN,Cr,NT-proBNP,LVDd,LVEF有显著变化(P<0.05或P<0.01),而收缩压、舒张压的变化不明显(P>0.05),血钾在各组治疗前后均无明显变化(P>0.05)。结论在常规心衰治疗基础上贝那普利与厄贝沙坦联合治疗更能减少慢性心衰的蛋白尿,改善心肾功能,提高临床疗效。
Objective To observe the efficacy of benazepril combined with irbesartan in the treatment of chronic heart failure with proteinuria. Methods A total of 116 patients with chronic heart failure and proteinuria were randomly divided into benazepril group (38 cases), irbesartan group (38 cases) and combination therapy group (40 cases) Beisitan and the combination of the two, 10 to 12 weeks after the observation of clinical efficacy and clinical changes. Results The total effective rate of combination therapy group was significantly better than that of benazepril and irbesartan group (P <0.05). UP, BUN, Cr, NT-proBNP, LVDd, systolic and diastolic blood pressure Compared with the other two groups, the levels of UP, BUN, Cr, NT-proBNP, LVDd and LVEF in the combined treatment group were significantly decreased (P <0.05 or P <0.01) (P <0.05 or P <0.01), while systolic and diastolic blood pressure did not change significantly (P> 0.05). There was no significant change in serum potassium before and after treatment (P> 0.05). Conclusion The combination of benazepril and irbesartan on the basis of routine heart failure treatment can reduce the proteinuria of chronic heart failure, improve heart and kidney function and improve clinical efficacy.